Alhaj H, Wisniewski G and McAllister-Williams H (2011) The use of the EEG in measuring therapeutic drug action: focus on depression and antidepressants. J Psychopharmacol 25: 1175--1191.
2.
Antonova E, Parslow D, Brammer M, Simmons A, Williams S, Dawson GR et al. (2011) Scopolamine disrupts hippocampal activity during allocentric spatial memory in humans: an fMRI study using a virtual reality analogue of the Morris Water Maze. J Psychopharmacol 25: 1256--1265.
3.
AlonsoJAngermeyerMCBernertSBruffaertsRBrughaTSBrysonHfor the ESEMeD/MHEDEA 2000 Investigators (2004) Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl420: 21–27.
4.
Bailey JE, Dawson GR, Dourish CT and Nutt DJ (2011a) Validation of the inhalation of 7.5% CO2 in healthy volunteers as a human experimental medicine model of GAD. J Psychopharmacol 25: 1192--1198.
5.
Bailey JE, Papadopoulos A, Diaper A, Phillips S, Schmidt M, van der Ark P, et al. (2011b) Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety. J Psychopharmacol 25: 1199--1206.
6.
CNS Drug Discoveries: Depression (2008) Pharmaceutical Market Research2008Espicom, August 2008.
7.
DiMasiJAHansenRWGrabowskiHG (2003) The price of innovation: new estimates of drug development costs. J Health Econ22: 151–185.
8.
Duka T, Crombag HS and Stephens DN (2011) Experimental medicine in drug addiction: towards behavioral, cognitive and neurobiological biomarkers. J Psychopharmacol 25: 1235--1255.
9.
HansenRAGartlehnerGLohrKNGaynesBNCareyTS (2005) Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med143: 415–426.
10.
Harmer CJ, Cowen PJ and Goodwin GM. (2011a) Efficacy markers in depression. J Psychopharmacol 25: 1148--1158.
11.
Harmer CJ, de Bodinat C, Dawson G, Dourish CT, Waldenmaier L, et al. (2011b) Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. J Psychopharmacol 25: 1148--1158.
12.
HowlandRHShuttLSBermanSRSpottsCRDenkoT (2011) The emerging use of technology for the treatment of depression and other neuropsychiatric disorders. Ann Clin Psychiatry23: 48–62.
13.
Koychev I, Barkus E, Ettinger U, Killcross S, Roiser JP, Wilkinson L, et al. (2011) Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia. J Psychopharmacol 25: 1207--1225.
14.
MillerG (2010) Is pharma running out of brainy ideas?Science329: 502–504.
15.
MunosB (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov8: 959–968.
16.
Murphy SE and Mackay CE (2011) Using MRI to measure drug action: caveats and new directions. J Psychopharmacol 25: 1168--1174.
17.
PangalosMNSchecterLEHurkoO (2007) Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov6: 521–532.
18.
Paterson LM, Nutt DJ and Wilson SJ (2011) Sleep and its disorders in translational medicine. J Psychopharmacol 25: 1226--1234.
19.
PringleABrowningMCowenPJHarmerCJ (2010) A cognitive neuropsychological model of antidepressant drug action. Prog Neuropsychopharmacol Biol Psychiatry00: 00–00.
20.
RickelsKDowningRSchweizerEHassmanH (1993) Antidepressants for the treatment of generalized anxiety disorder: A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psych50: 884–895.
UhlenhuthEHBalterMBBanTAYangKV (1999) International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992–1997. Depress Anxiety9: 107–116.
23.
van OsJHanssenMBijlRVRavelliA (2000) Strauss (1969) revisited: a psychosis continuum in the general population?Schizophr Res45: 11–20.
